Retraction—Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
The COOPERATE study had previously been looked upon as providing support for combination ACE inhibitor and ARB therapy in proteinuric patients with non-diabetic kidney disease. After an initial letter of concern, the Lancet has retracted the paper after the results of an academic investigation indicated serious concerns surrounding this publication. These include that the trial had not been approved by the hospital ethics committee, proper consent from patients had not been obtained, the involvement of a statistician could not be verified, the trial was not a double-blind study, and based on a sample of the medical records the authenticity of the data could not be proved.
- Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients
- Persistent Asymptomatic Isolated Microscopic Hematuria in Israeli Adolescents and Young Adults and Risk for End-Stage Renal Disease
- Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes